Fresenius Appoints Michael Sen as CEO

Fresenius announced that Michael Sen (53) will become CEO of the company on October 1, succeeding Stephan Sturm (59) who will “leave the company on good terms” on September 30.
 
Sen will also keep serving as Fresenius Kabi CEO until a successor is chosen. He’s been responsible for Fresenius Kabi since April 2021. He was a member of Siemens’ management board previously, responsible for Siemens Healthineers and the company’s energy business. Sen was CFO of E.ON SE from 2015 to 2017.
 
Sturm has a on Fresenius’ management board since 2005, starting as CFO, and became Fresenius CEO on July 1, 2016.
 
“Fresenius has always been more than just a job to me,” Sturm told the press. “This company was and is still close to my heart. I look back with gratitude and pride on my more than 17 years here, during which we accomplished a lot together and developed Fresenius into a leading global healthcare company—one that provides ever more people with ever better medicine. I’m especially thankful for the many colleagues with whom I was privileged to work, and with whom I will remain connected even after my time at Fresenius. This is a great company, with outstanding growth prospects.”
 
“I’m very pleased about the trust being placed in me and in my capabilities,” said Sen. “I am taking on leading this company, which brings both great responsibility and excitement, with respect but above all with great joy and confidence. This is because, despite the temporary challenges and headwinds we encounter, our prospects for achieving future success are very promising: The markets we are active in are fundamentally attractive, and our businesses in many areas are strongly positioned. Being agile and taking prudent strategic decisions will enable us to tap into our full potential and accelerate our growth dynamics again. Together with my Management Board colleagues and all our employees, I will devote my full energy to this. Fresenius is a fantastic company that creates value in so many ways, and I have a strong personal commitment to advancing innovation in medicine for the health and well-being of all people. I want to contribute so that, going forward, all our stakeholders will benefit even more from an even stronger Fresenius.”